Livewell

What Livewell does

Livewell was a Canadian direct-to-consumer digital health and telehealth platform founded in 2022 and headquartered in Montréal, focused primarily on medical weight loss. The company served individual Canadian consumers entirely online, offering personalized treatment plans across weight loss, acne, birth control, and erectile dysfunction categories. Its core weight loss offering centered on access to GLP-1 and related medications — including Ozempic, Wegovy, Mounjaro, Saxenda, Contrave, Zepbound, Rybelsus, and generic semaglutide — delivered through online consultations with licensed providers and prescriptions shipped directly to patients.

The business operated on a subscription-recurring model in which customers paid recurring fees for treatment plans featuring 100% online treatments, free shipping, unlimited provider follow-ups, discreet unmarked packaging, and free cancellation. Go-to-market was self-serve and digital-first, with customers completing online health assessments and consulting providers via the web platform. Specific pricing was not publicly disclosed.

In December 2025, Livewell was acquired by Hims & Hers Health, Inc. as part of that company's international expansion into Canada, timed to the expiration of Novo Nordisk's Canadian semaglutide patent and the anticipated availability of generic semaglutide. Following the transition (effective as of June 30, 2025), the Livewell brand was retired and operations migrated to the hims.ca and forhers.ca domains under Hims & Hers Canada, Inc. Co-founders Antoine Arbour and Patrick Duffy joined the Canadian team under new General Manager Austin Kouri.

Name

Livewell

Legal name

Livewell

Website

https://joinlivewell.ca

Company type

Private

Operating status

Acquired

Headcount range

11–50 employees

Short description

Livewell is a Canadian direct-to-consumer digital telehealth platform, founded in 2022 and focused on medical weight loss, offering GLP-1 medications and treatments for acne, birth control, and erectile dysfunction to Canadian consumers online. Acquired by Hims & Hers in December 2025.

Ownership category

akta.pro rank

Headquarters

HQ city

Montréal

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Operations, Personnel, Marketing or Sales, Technology or R&D, Supply Chain

Revenue model

1. Telehealth subscription services: Subscription-based telehealth model offering online treatments across weight loss, acne, birth control, and erectile dysfunction categories. Customers pay recurring subscription fees for personalized treatment plans with 100% online delivery, free shipping, and unlimited follow-ups. Revenue generated through recurring subscription charges.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Livewell is a Canadian digital health and telehealth platform that connects consumers with licensed medical providers for online consultations and prescriptions. It offers personalized treatment plans across weight loss (including GLP-1 medications such as Ozempic, Wegovy, Mounjaro, and generic semaglutide), acne, birth control, and erectile dysfunction, with medications shipped directly to customers via free, discreet delivery. The platform operates on a subscription basis with unlimited follow-ups and free cancellation.

Product overview

Livewell was a Canadian digital health and telehealth platform focused on weight loss treatment, which was acquired by Hims & Hers Health, Inc. and transitioned to become Hims & Hers Canada as of June 30, 2025. The platform provides a unified digital healthcare offering combining multiple care categories (Weight Loss, Acne, Birth Control, Erectile Dysfunction) with an online pharmacy service providing access to GLP-1 and other weight management medications (Ozempic, Wegovy, Mounjaro, Saxenda, Contrave, Zepbound, Rybelsus, Semaglutide). The platform features 100% online treatments with free shipping, unlimited follow-ups, and discreet packaging, positioning itself as a personalized healthcare solution for Canadians.

Differentiator

Problem solved

Functional benefit

Products and services

• Weight Loss Treatment Program Personalized weight loss treatment program offered through the digital telehealth platform, providing Canadian consumers with access to GLP-1 medications (including Ozempic, Wegovy, Mounjaro, Saxenda, Contrave, Zepbound, Rybelsus, and generic semaglutide) for obesity and diabetes management.
• Acne Treatment Online acne treatment service providing personalized skincare treatments and prescriptions through the platform for Canadian consumers.
• Birth Control Online birth control prescription and delivery service providing convenient access to contraceptive medications for Canadian consumers.
• Erectile Dysfunction Treatment Online erectile dysfunction treatment service providing prescription medications and consultations for Canadian consumers seeking discreet ED care.
• Semaglutide Medication Portfolio Portfolio of GLP-1 and related weight-loss medications (Ozempic, Wegovy, Mounjaro, Saxenda, Contrave, Zepbound, Rybelsus, and generic semaglutide) available through online consultations and prescriptions.
• Labs Biomarker Testing Biomarker diagnostic testing service offering up to 120 lab tests through a partnership with Quest Diagnostics, expanding the platform's diagnostics capabilities for Canadian consumers.

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Two partnerships are on record, tiered core.

• Novo NordiskcoreOthers · 1 December 2025Novo Nordisk's Canadian patent expiration for semaglutide enabled Livewell/Hims & Hers Canada to launch weight loss programs in Canada featuring generic semaglutide options. The broader Hims & Hers organization also formed a strategic collaboration with Novo Nordisk for FDA-approved GLP-1 treatments, though Livewell's specific arrangement relates to generic product availability following patent expiry.
• Pharmaceutical manufacturers (Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus, Saxenda, Contrave)coreOthersLivewell/Hims & Hers Canada offers prescription medications including Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus, Saxenda, and Contrave as part of its telehealth offering. These branded pharmaceutical products are available through online consultations and prescriptions delivered to Canadian patients.

Scale indicators2 records

Recent moves7 records

Expansion highlights4 records

Direct peers

• Maple: Canadian telehealth platform offering online doctor consultations and prescriptions across multiple categories, directly comparable to Livewell's D2C telehealth model serving Canadian consumers.
• Ro: US-based D2C telehealth platform offering weight loss (Ro Body), men's and women's health treatments, with a similar subscription-based model and direct-to-consumer online delivery.
• Felix Health: Canadian online health platform offering prescription treatments across multiple categories including sexual health and weight management, directly competing in the same Canadian telehealth market.
• Tia Health: Canadian virtual care platform offering online doctor consultations and prescription services, operating in the same Canadian telehealth market as Livewell.

Emerging players

• Sesame: Online healthcare marketplace connecting patients with providers for consultations and prescriptions including weight loss medications, with similar DTC telehealth approach and online pharmacy delivery.
• Alpha Medical: US-based telehealth platform focused on primary care and women's health including weight management, offering online consultations and prescription delivery with comparable D2C model.

Broad incumbents

• Hims & Hers Health: Parent company that acquired Livewell, operating a broader US-based telehealth platform across men's and women's health categories including weight loss, sexual health, and skin care with similar subscription-based model.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks4 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/join-livewell

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Livewell